Industry
Pharmaceuticals
Developers of branded and generic drugs. Value creation rests on R&D pipelines, patent lifecycles, regulatory approvals and pricing power versus payers.
Total Companies
1 315
1 264 stocks
| Company | Last Price | Price Change | Market Cap | ||
|---|---|---|---|---|---|
|
|
|
Eli Lilly and Co
LLY
|
$1 196.03 |
+0.9%
|
$1.1T |
|
|
|
Johnson & Johnson
JNJ
|
$263.4 |
+1.6%
|
$634.1B |
|
|
|
Merck & Co Inc
MRK
|
$131.07 |
+0.5%
|
$323.7B |
|
|
|
Roche Holding AG
ROG
|
CHf324.9 |
+4.1%
|
$321.9B |
|
|
|
Novartis AG
NOVN
|
CHf127.34 |
-0.3%
|
$297.5B |
|
|
|
AstraZeneca PLC
AZN
|
12 670 |
-0.1%
|
$261.7B |
|
|
|
Novo Nordisk A/S
NOVO B
|
kr324.15 |
+1.2%
|
$218.3B |
|
|
|
Nuvo Pharmaceuticals Inc
MRV
|
CA$34.04 |
-1%
|
$176.8B |
|
|
|
Pfizer Inc
PFE
|
$24.54 |
-0.2%
|
$139.9B |
1 259 results hidden
Create a free account to unlock additional access and upgrade to see all results
Create Free Account
